Insider trading has long been a key enforcement priority for the U.S. Securities and Exchange Commission (SEC) and the U.S. Department of Justice (DOJ). Life sciences companies, along with their executives and directors, have already — and will continue to — face scrutiny arising out of event-driven trading issues relating to COVID-19 diagnostics, treatments, and vaccines share Goodwin Complex Litigation & Dispute Resolution members Annie Railton and Courtney Orazio. Read the by-line in New York University School of Law’s Program on Corporate Compliance & Enforcement Blog here.